In similar studies, TME modulation has greatly improved outcomes of BsAb-based T cell immunotherapy, where anti-Gr-1, anti-Ly6G, or anti-Ly6C antibodies to deplete MDSCs or clodronate liposome or anti-CSF1R antibodies to deplete TAMs were effectively combined with GD2-EATs or HER2-EATs for treating osteosarcoma [147]. The gene discussed is ERBB2; the disease is osteosarcoma.